Investor relations, page-3

Yes. I got an email from Stuart Roberts appreciating my support for 'Imugene's efforts on new treatments for cancer patients' over the past year or so. He provided his mobile number if I had questions or comments re the company.

I'm probably one of the more substantial holders (6.5 million shares) so he may just have been acknowledging that fact.

As it happens I'm quite happy with the way the Company is travelling. I'm impressed with the quality of (and need for) the technology, Management, the scientists and other personnel, plus the professional way they are progressing, and proving, the viability of Her-vax.

Almost 50% of my portfolio is biotech or medical related. I've got reasonable size holdings in NEU, AVH, PGC, etc., all of which I'm reasonably confident about. (Mind you, IMU is the only one that has contacted me so that probably says something about them covering their bases, i.e. their communication and mgmt skills).

I see IMU as a really cheap entry level investment in the new/innovative 'turn on the body's natural defences to fight different types of cancer, area.

Compared to it's peers it has a really low market cap, has attracted major talent from existing large and successful competitors, and appears to, hopefully, have a superior product to Herceptin, the 'existing standard of care'.

In my opinion, one of the best punts that I have come across. But time will tell.

Anyway, thats my two bobs worth.

Donos.

GLTAH.